PULSION: Preliminary figures for the financial year 2007
EBIT rises to EUR 4.1 million (+21%) in line with forecast / Sales revenue of EUR 28.3 million (+16%) / Capital expenditure at high level / Liquid assets increased once again
Operating profit (EBIT) improved by 21% to EUR 4.1 million (2006: EUR 3.4 million) in line with forecast. The gross margin fell by 2 percentage points from 75% to 73%, primarily as a result of the changed sales mix, lower margins on monitor sales and the pronounced increase of sales revenue generated in the USA where lower margins have so far been achieved.
Earnings before tax (EBT) climbed from EUR 3.3 million in 2006 to EUR 4.0 million in 2007. At EUR 3.9 million, capital expenditure remained at a high level (2006: EUR 2.9 million). Liquid assets (including available-for-sale financial assets) nevertheless increased in 2007 from EUR 5.2 million to EUR 7.0 million.
"We have invested large amounts of time and money in our strategy for the future. Most of the expenditure was on product development, streamlining production and also on new sales and marketing strategies. Although we are not entirely satisfied with the16 percent sales revenue increase to Euro 28.3 million, we nevertheless succeeded in increasing EBIT by 21%", says Bradley Gould, CEO of PULSION Medical Systems AG.
The complete and audited consolidated financial statements will be made public on March 20, 2008.
PULSION Medical Systems SE
PULSION Medical Systems AG, founded in 1990, has become one of the leading specialists for intelligent medical diagnosis and therapy management systems and has been listed on the Stock Exchange in Frankfurt since 2001. The repeated development of innovative product lines in the medtech field is the basis for creation and expansion of the attractive disposable business with sterile products and pharmaceuticals.
The business unit PULSION Critical Care covering intensive care medicine, perioperative medicine and emergency medicine focuses on the management of cardiovascular and organ functions of critically ill patients. Products and activities of the business unit PULSION Perfusion are directed at the diagnosis and therapy management of organ and tissue perfusion in ophthalmology, surgery and hepatology.
PULSION products are marketed worldwide via own sales channels or secondary distribution. All products are certified with the CE mark which is basis for marketing in the EU and some other countries. The US-American FDA approval and the Japanese market approval have been issued for selected product lines.
Further information about PULSION is available at www.pulsion.com.
PULSION Medical Systems AG
ISIN DE0005487904 Equity capital: Euro 9,577,302 divided into no-par-value euro 1 individual share certificates